Skip to content

To explore the application value of high frequency ultrasound in evaluating the effect of Simiao powder in the treatment of gouty arthritis based on the study of histopathology and multi-omics

To explore the application value of high frequency ultrasound in evaluating the effect of Simiao powder in the treatment of gouty arthritis based on the study of histopathology and multi-omics

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2200005890
Enrollment
Unknown
Registered
2022-04-20
Start date
2022-04-20
Completion date
Unknown
Last updated
2023-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

damp heat accumulation type gouty arthritis

Interventions

case group:Simiao powder Treatment

Sponsors

Guang'anmen Hospital of China Academy of Chinese Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
20 Years to 60 Years

Inclusion criteria

Inclusion criteria: 1) The disease diagnosis meets the 2015 ACR/EULAR gout classification criteria; 2) The first visit was in the acute stage of gout (the attack time was less than 7 days), with knee joint swelling and pain as the main joint symptom; 3) Ultrasound examination showed clear knee joint effusion, synovial membrane, "double track sign" or crystal deposition or tophi; 4) Meet the diagnostic criteria of TCM syndromes of damp-heat accumulation syndrome; 5) Age between 20-60 years old. 6) Voluntarily participate in the trial and sign the informed consent.

Exclusion criteria

Exclusion criteria: 1) Patients with gout caused by certain drugs (such as proton pump inhibitors, low-dose aspirin, etc.), tumor radiotherapy and chemotherapy, etc. or secondary to diseases such as kidney disease, blood disease, and xanthine urethral deposition; 2) The first diagnosis is in the non-acute stage of gout; 3) Combined with other rheumatic diseases such as osteoarthritis and rheumatoid arthritis; 4) Those with other knee joint diseases: such as knee joint septic arthritis, knee joint traumatic arthritis, etc.; 5) Acute exacerbated or poorly controlled chronic diseases such as hypertension, coronary heart disease, liver and kidney insufficiency; 6) Mental illness, lack of self-control, unable to express accurately or unable to cooperate with treatment. 7) Those with abnormal coagulation function.

Design outcomes

Primary

MeasureTime frame
Biochemical Indicators;

Secondary

MeasureTime frame
Ultrasonic indicators;6/5000 Clinical symptom index;

Countries

china

Contacts

Public ContactGUO Ling
guoling0726@163.com13671031526

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026